Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 22, 2024 at 04:05 pm EST
Share
Vir Biotechnology, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 16.79 million compared to USD 49.41 million a year ago. Net loss was USD 115.97 million compared to USD 101.6 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.76 a year ago. Diluted loss per share from continuing operations was USD 0.86 compared to USD 0.76 a year ago.
For the full year, revenue was USD 86.18 million compared to USD 1,615.8 million a year ago. Net loss was USD 615.06 million compared to net income of USD 515.84 million a year ago. Basic loss per share from continuing operations was USD 4.59 compared to basic earnings per share from continuing operations of USD 3.89 a year ago. Diluted loss per share from continuing operations was USD 4.59 compared to diluted earnings per share from continuing operations of USD 3.83 a year ago.
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
VIR BIOTECHNOLOGY, INC. 
